Application No.	Drug	Applicant
ANDA 88–015	THEO–DUR (Theophylline Sustained-release Capsules) Sprinkle, 75 mg	Do.
ANDA 88–016	THEO–DUR (Theophylline Sustained-release Capsules) Sprinkle, 125 mg	Do.
ANDA 88–022	THEO–DUR (Theophylline Sustained-release Capsules) Sprinkle, 50 mg	Do.
ANDA 88–066	Hydrocone Bitartrate and Homatropine Methylbromide Syrup, 5 mg/1.5 mg per5 mL	Halsey Drug Co., 1827 Pacific St., Brooklyn, NY 11233.
ANDA 88–112	Tripodrine (Triprolidine and Pseudoephedrine Hydrochlorides Tablets USP) 2.5 mg/60 mg	Danbury Pharmacal, Inc., 131 West St., Danbury, CT 06810.
ANDA 88–140	Chlorthalidone Tablets USP, 50 mg	Purepac Pharmaceutical.
ANDA 88–178	Hydralazine Hydrochloride Tablets, 50 mg	Do.
ANDA 88–360	Fluocinolone Acetonide Cream USP, 0.025%	Alpharma.
ANDA 88–361	Fluocinolone Acetonide Cream USP, 0.01%	Do.
ANDA 88–950	Tolbutamide Tablets, 500 mg	Purepac Pharmaceutical.
ANDA 88–997	Dexamethasone Elixir USP, 0.5 mg/5 mL	Alpharma.
ANDA 89–754	Hydrocortisone Cream USP, 2.5%	Do.
ANDA 89–840	Procainamide Hydrochloride Extended-release Tablets, 500 mg	Inwood Laboratories.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the applications listed in the table in this document, and all amendments and supplements thereto, is hereby withdrawn, effective September 25, 1997.

Dated: September 11, 1997.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 97–25369 Filed 9–24–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Delegation of Authority

Notice is hereby given that I have delegated to the Director, Centers for Disease Control and Prevention, with authority to redelegate, the following authorities vested in the Secretary of Health and Human Services under Title XXVI of the Public Health Service Act, ''Health Care Services Program,'' and the Ryan White Care Act Amendments of 1996 (P.L. 104–146), as amended hereafter, insofar as these authorities pertain to the functions assigned to the Centers for Disease Control and Prevention:

Section 2625—CDC Guidelines for Pregnant Women
Section 2626—Perinatal Transmission of HIV Disease; Contingent Requirement Regarding State Grants Under This Part
Section 2628—Report by the Institute of Medicine
Sections 2641–2650—Formula Grants for States
Sections 2661–2667—General Provisions
Section 2675—Coordinaiton
Section 2680—Grants to States and political subdivisions of States to implement guidelines and model curriculum for health workers and public safety workers, including emergency response employees.
Sections 2681–2690—Notificaiton of Possible Exposure to Infectious Diseases

The Centers for Disease Control and Prevention and the Health Resources and Services Administration shall cooperate in the implementation of Section 2626(e).

This delegation shall be excised under the Department's existing delegation of authority and policy on regulations.

This delegation became effective upon date of signature. In addition, I have affirmed and ratified any actions taken by the Director, Centers for Disease Control and Prevention or his subordinates which involved the exercise of the authorities delegated herein prior to the effective date of the delegation.

Dated: September 15, 1997.

Donna E. Shalala,

Secretary.

[FR Doc. 97–25467 Filed 9–24–97; 8:45 am]

BILLING CODE 4160–18–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration

[Document Identifier: HCFA–R–97]

Agency Information Collection Activities: Submission for OMB Review; Comment Request

AGENCY: Health Care Financing Administration.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Type of Information Collection Request: Reinstatement, without change, of a previously approved collection for which approval has expired; *Title of Information Collection:* Requirement to Disclose HMO Financial Information to Members and Supporting Regulations in 42 CFR 417.124; *Form No.:* HCFA–R–0097 (OMB 0938–0472); *Use:* Federally